Catalyst calendar
The repricing schedule is mostly public if you actually look at it.
AllI · Sterile fill-finish capacityII · Stoppers, syringes & drug-contact componentsIII · Pharmaceutical glass & vialsIV · Bioprocessing consumables & resinsV · API & small-molecule reshoringVI · CDMO capacity & the China exodusVII · Peptide & oligonucleotide manufacturingVIII · Sterile injectables & shortage economicsIX · Analytical instruments & QC releaseX · Private giants & exposure vehicles
August 2026
- 04mediumEarningsSTVNStevanato Group Q2 2026 resultsQuantifies GLP-1 device-format demand (Nexa syringes, EZ-fill) and the Fishers, Indiana ramp — the clearest US-listed read on whether fill-finish component capacity is tightening or easing.
- 05mediumEarningsNVONovo Nordisk H1 2026 financial resultsCompany-confirmed 07:30 CEST print that details utilization of the three acquired Catalent fill-finish sites and remaining semaglutide/Wegovy supply constraints — the captive end of the fill-finish choke.
October 2026
- 22mediumEarningsWSTWest Pharmaceutical Q3 2026 resultsReads through to component (stopper/Crystal Zenith) demand and the 49%-owned Daikyo Seiko affiliate — the most central US-listed proxy for the injectable drug-delivery component chokepoint.
- 06lowConferenceCPHI Worldwide 2026 (Oct 6-8)The global pharma-manufacturing supply-chain meeting where CDMO capacity signals (biologics drug substance, aseptic fill-finish) and BIOSECURE re-shoring intent are set — directly drives the supplier-qualification choke this vertical tracks.